{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:25:45Z","timestamp":1793453145523,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jacig.2022.10.003","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T12:56:21Z","timestamp":1670936181000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["The conundrum of COVID-19 mRNA vaccine\u2013induced anaphylaxis"],"prefix":"10.1016","volume":"2","author":[{"given":"Muhammad Bilal","family":"Khalid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela A.","family":"Frischmeyer-Guerrerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2022.10.003_bib1","doi-asserted-by":"crossref","first-page":"631736","DOI":"10.3389\/fmicb.2020.631736","article-title":"Pandemics throughout history","volume":"11","author":"Piret","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jacig.2022.10.003_bib3","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2022.10.003_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2022.10.003_bib5","unstructured":"WHO coronavirus (COVID-19) dashboard. Geneva, Switzerland: World Health Organization; 2020. Available at: https:\/\/covid19.who.int\/. Accessed May 26, 2022."},{"key":"10.1016\/j.jacig.2022.10.003_bib8","unstructured":"DailyMed. Moderna COVID-19 vaccine (cx-024414) injection, suspension. Nih.gov. Last Updated: October 17, 2022. Available at: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo. Accessed May 26, 2022."},{"key":"10.1016\/j.jacig.2022.10.003_bib9","unstructured":"DailyMed - PFIZER-BIONTECH COVID-19 VACCINE- bnt162b2 injection, suspension. Last Updated: December 12, 2022. Nih.gov. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo. Accessed May 26, 2022."},{"key":"10.1016\/j.jacig.2022.10.003_bib10","doi-asserted-by":"crossref","first-page":"103479","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.jacig.2022.10.003_bib11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41565-022-01071-x","article-title":"Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines","volume":"17","author":"Szebeni","year":"2022","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.jacig.2022.10.003_bib12","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.jaci.2021.04.002","article-title":"Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines","volume":"147","author":"Risma","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib13","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.anai.2017.01.009","article-title":"Mechanisms of anaphylaxis beyond classically mediated antigen- and IgE-induced events","volume":"118","author":"Lieberman","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","article-title":"Vaccine-associated hypersensitivity","volume":"141","author":"McNeil","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib15","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1111\/bcp.14112","article-title":"Immune-mediated adverse reactions to vaccines","volume":"85","author":"Stone","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacig.2022.10.003_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.02.2012.5797","article-title":"Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80","volume":"2012","author":"Badiu","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jacig.2022.10.003_bib17","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/cea.12760","article-title":"Immediate-type hypersensitivity to polyethylene glycols: a review","volume":"46","author":"Wenande","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jacig.2022.10.003_bib18","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jaip.2018.12.003","article-title":"Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized","volume":"7","author":"Stone","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib19","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaip.2020.09.029","article-title":"Polyethylene glycol-induced systemic allergic reactions (anaphylaxis)","volume":"9","author":"Sellaturay","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2021.05.020","article-title":"Optimizing investigation of suspected allergy to polyethylene glycols","volume":"149","author":"Bruusgaard-Mouritsen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib21","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jaip.2020.11.011","article-title":"Anti-PEG IgE in anaphylaxis associated with polyethylene glycol","volume":"9","author":"Zhou","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib22","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jaip.2020.12.047","article-title":"mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach","volume":"9","author":"Banerji","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.anai.2021.11.006","article-title":"Utility and futility of skin testing to address concerns surrounding messenger RNA coronavirus disease 2019 vaccine reactions","volume":"128","author":"Pitlick","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib24","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.jaip.2021.06.006","article-title":"The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach","volume":"9","author":"Greenhawt","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib25","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1016\/j.jaip.2021.06.010","article-title":"First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing","volume":"9","author":"Wolfson","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib26","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1111\/all.14958","article-title":"Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don\u2019t give up on the second dose!","volume":"76","author":"Krantz","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2022.10.003_bib27","doi-asserted-by":"crossref","first-page":"e2125524","DOI":"10.1001\/jamanetworkopen.2021.25524","article-title":"Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system","volume":"4","author":"Warren","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacig.2022.10.003_bib28","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/all.15178","article-title":"COVID-19 vaccines tolerated in patients with paclitaxel and docetaxel allergy","volume":"77","author":"Banerji","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2022.10.003_bib29","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jaip.2021.09.051","article-title":"mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase","volume":"10","author":"Koo","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib30","doi-asserted-by":"crossref","first-page":"e29295","DOI":"10.1002\/pbc.29295","article-title":"Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase","volume":"68","author":"Mark","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jacig.2022.10.003_bib31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.anai.2022.03.006","article-title":"COVID-19 vaccine administration in patients with reported reactions to polyethylene glycol- and polysorbate-containing therapeutics","volume":"29","author":"Otani","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib32","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jaip.2021.11.021","article-title":"Safety of COVID-19 vaccination in patients with polyethylene glycol allergy: a case series","volume":"10","author":"Picard","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib33","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1111\/all.15183","article-title":"Experience with polyethylene glycol allergy-guided risk management for COVID-19 vaccine anaphylaxis","volume":"77","author":"Brockow","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2022.10.003_bib34","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaip.2018.08.035","article-title":"Anaphylaxis to trometamol excipient in gadolinium-based contrast agents for clinical imaging","volume":"7","author":"Lukawska","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib35","doi-asserted-by":"crossref","first-page":"414","DOI":"10.18176\/jiaci.0773","article-title":"Hypersensitivity to the Moderna COVID-19 vaccine caused by tromethamine: PEG is not always the culprit excipient","volume":"32","author":"Rama","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib36","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154-155","author":"Kozma","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jacig.2022.10.003_bib37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in\u00a0blood\u00a0triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib38","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1182\/blood.2020008248","article-title":"Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition","volume":"136","author":"Yu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jacig.2022.10.003_bib39","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2021.02.013","article-title":"Mechanisms of human drug-induced anaphylaxis","volume":"147","author":"Bruhns","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa070030","article-title":"Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis","volume":"358","author":"Vadas","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2022.10.003_bib41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2013.08.016","article-title":"Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States","volume":"133","author":"Wood","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib42","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaci.2015.07.048","article-title":"Risk of anaphylaxis after vaccination in children and adults","volume":"137","author":"McNeil","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib43","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jaci.2013.10.029","article-title":"Case fatality and population mortality associated with anaphylaxis in the United States","volume":"133","author":"Ma","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib44","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jaci.2018.12.1003","article-title":"Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016","volume":"143","author":"Su","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib45","doi-asserted-by":"crossref","first-page":"m4780","DOI":"10.1136\/bmj.m4780","article-title":"Covid-19: people with history of significant allergic reactions should not receive Pfizer vaccine, says regulator","volume":"371","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jacig.2022.10.003_bib46","author":"Clark"},{"key":"10.1016\/j.jacig.2022.10.003_bib47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.15585\/mmwr.mm7002e1","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine\u2014United States, December 14-23, 2020","volume":"70","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jacig.2022.10.003_bib48","doi-asserted-by":"crossref","first-page":"125","DOI":"10.15585\/mmwr.mm7004e1","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine\u2014United States, December 21, 2020-January 10, 2021","volume":"70","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jacig.2022.10.003_bib49","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US\u2014December 14, 2020-January 18, 2021","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacig.2022.10.003_bib50","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1001\/jama.2021.3976","article-title":"Acute allergic reactions to mRNA COVID-19 vaccines","volume":"325","author":"Blumenthal","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacig.2022.10.003_bib51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13223-021-00613-7","article-title":"Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a\u00a0systematic review and meta-analysis","volume":"17","author":"Alhumaid","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib52","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaip.2021.12.021","article-title":"Population-based incidence, severity, and risk factors associated with treated acute-onset COVID-19 mRNA vaccination-associated hypersensitivity reactions","volume":"10","author":"Macy","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib53","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacig.2022.10.003_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12948-022-00167-y","article-title":"The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis","volume":"20","author":"Sobczak","year":"2022","journal-title":"Clin Mol Allergy"},{"key":"10.1016\/j.jacig.2022.10.003_bib55","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.vaccine.2021.11.066","article-title":"Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines","volume":"40","author":"Maltezou","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jacig.2022.10.003_bib56","unstructured":"Hhs.gov. Vaccine adverse event reporting system (VAERS). Last reviewed December 12, 2022. Available at: https:\/\/vaers.hhs.gov\/. Accessed May 26, 2022."},{"key":"10.1016\/j.jacig.2022.10.003_bib57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.anai.2021.03.024","article-title":"Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines","volume":"127","author":"Kelso","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib58","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamainternmed.2021.8515","article-title":"Risk of second allergic reaction to SARS-CoV-2 vaccines: a systematic review and meta-analysis","volume":"182","author":"Chu","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacig.2022.10.003_bib59","doi-asserted-by":"crossref","first-page":"e13683","DOI":"10.1111\/pai.13683","article-title":"Second dose of COVID-19 vaccination in immediate reactions to the first BNT162b2","volume":"33","author":"Rosa Duque","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib60","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2021.01.004","article-title":"mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis","volume":"147","author":"Rama","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib61","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1016\/j.jaip.2021.05.010","article-title":"Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome","volume":"9","author":"Kaakati","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib62","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jaip.2022.01.037","article-title":"COVID-19 vaccination in the setting of mastocytosis-Pfizer-BioNTech mRNA vaccine is safe and well tolerated","volume":"10","author":"Lazarinis","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib63","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jaip.2022.01.030","article-title":"Safety of COVID-19 vaccination in patients with clonal mast cell disorders","volume":"10","author":"Ruano-Zaragoza","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib64","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1097\/HS9.0000000000000650","article-title":"A UK survey examining the experience of adults with mastocytosis receiving COVID-19 vaccination","volume":"5","author":"Sriskandarajah","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.jacig.2022.10.003_bib65","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3390\/vaccines10050718","article-title":"COVID-19 vaccination is safe among mast cell disorder patients, under adequate premedication","volume":"10","author":"Rama","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jacig.2022.10.003_bib66","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.anai.2018.11.014","article-title":"Drug allergy in children and adults: is it the double X chromosome?","volume":"122","author":"Eaddy Norton","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib67","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/j.1398-9995.2008.01880.x","article-title":"Gender difference, sex hormones, and immediate type hypersensitivity reactions","volume":"63","author":"Chen","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2022.10.003_bib68","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1016\/j.vaccine.2021.04.066","article-title":"Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines","volume":"39","author":"Somiya","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jacig.2022.10.003_bib69","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","article-title":"Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals","volume":"88","author":"Chen","year":"2016","journal-title":"Anal Chem"},{"key":"10.1016\/j.jacig.2022.10.003_bib70","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.3390\/molecules23071700","article-title":"Understanding the role of anti-PEG antibodies in the complement activation by Doxil in\u00a0vitro","volume":"23","author":"Neun","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.jacig.2022.10.003_bib71","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.vaccine.2017.11.017","article-title":"Anxiety-related adverse events following immunization (AEFI): a systematic review of published clusters of illness","volume":"36","author":"Loharikar","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jacig.2022.10.003_bib72","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1016\/j.vaccine.2020.02.046","article-title":"Immunization stress-related response\u2014redefining immunization anxiety-related reaction as an adverse event following immunization","volume":"38","author":"Gold","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jacig.2022.10.003_bib74","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.jaip.2021.05.031","article-title":"Allergic symptoms after mRNA COVID-19 vaccination and risk of incomplete vaccination","volume":"9","author":"Robinson","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib75","doi-asserted-by":"crossref","first-page":"e2143955","DOI":"10.1001\/jamanetworkopen.2021.43955","article-title":"Frequency of adverse events in the placebo arms of COVID-19 vaccine trials: a systematic review and meta-analysis","volume":"5","author":"Haas","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacig.2022.10.003_bib76","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jiac.2022.02.002","article-title":"Investigation\u00a0of\u00a0the incidence of immunisation stress-related response following\u00a0COVID-19 vaccination in healthcare workers","volume":"28","author":"Takano","year":"2022","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jacig.2022.10.003_bib77","doi-asserted-by":"crossref","first-page":"100472","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World Allergy Organization anaphylaxis guidance 2020","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jacig.2022.10.003_bib78","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jaci.2020.01.017","article-title":"Anaphylaxis\u2014a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis","volume":"145","author":"Shaker","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib79","doi-asserted-by":"crossref","first-page":"6714","DOI":"10.1016\/j.vaccine.2020.08.044","article-title":"Immunization stress-related responses presenting as psychogenic non-epileptic seizures following HPV vaccination in Rio Branco, Brazil","volume":"38","author":"Marchetti","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jacig.2022.10.003_bib80","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1001\/jamainternmed.2021.3779","article-title":"Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose","volume":"181","author":"Krantz","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacig.2022.10.003_bib81","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.anai.2021.08.417","article-title":"Coronavirus disease 2019 vaccine hypersensitivity evaluated with vaccine and excipient allergy skin testing","volume":"128","author":"Kohli-Pamnani","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib82","doi-asserted-by":"crossref","first-page":"ofab507","DOI":"10.1093\/ofid\/ofab507","article-title":"Graded administration of second dose of Moderna and Pfizer-BioNTech COVID-19 mRNA vaccines in patients with hypersensitivity to first dose","volume":"8","author":"Tuong","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jacig.2022.10.003_bib83","doi-asserted-by":"crossref","first-page":"825164","DOI":"10.3389\/falgy.2022.825164","article-title":"Successful desensitization to mRNA COVID-19 vaccine in a case series of patients with a history of anaphylaxis to the first vaccine dose","volume":"3","author":"AlMuhizi","year":"2022","journal-title":"Front Allergy"},{"key":"10.1016\/j.jacig.2022.10.003_bib84","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jaip.2017.06.021","article-title":"Anaphylaxis and clinical utility of real-world measurement of acute serum tryptase in UK emergency departments","volume":"5","author":"Buka","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib85","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.anai.2015.07.019","article-title":"Anaphylaxis\u2014a practice parameter update 2015","volume":"115","author":"Lieberman","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib86","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.jaip.2022.02.025","article-title":"Vocal cord dysfunction\/inducible laryngeal obstruction(s) mimicking anaphylaxis during SARS-CoV-2 (COVID-19) vaccination","volume":"10","author":"Leong","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib87","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.anai.2021.10.009","article-title":"Polyethylene glycol and polysorbate testing in 12 patients before or after coronavirus disease 2019 vaccine administration","volume":"128","author":"Carpenter","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib88","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.anai.2021.10.019","article-title":"Allergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy: Northwell Health experience","volume":"128","author":"Kaplan","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib89","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jaci.2022.03.023","article-title":"Rapid progress in our understanding of Covid-19 vaccine allergy: a cause for optimism, not hesitancy","volume":"150","author":"Banerji","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib90","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaci.2012.04.003","article-title":"Adverse reactions to vaccines practice parameter 2012 update","volume":"130","author":"Kelso","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib91","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jaip.2021.03.022","article-title":"Nonirritant concentrations for skin testing with SARS-CoV-2 mRNA vaccine","volume":"9","author":"Marcelino","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2022.10.003_bib92","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.anai.2021.09.021","article-title":"Evaluation of anaphylaxis risk by skin\u00a0testing with coronavirus disease 2019 messenger RNA vaccines\u00a0on\u00a0patients with anaphylaxis","volume":"128","author":"Pienkowski","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2022.10.003_bib93","doi-asserted-by":"crossref","first-page":"e12152","DOI":"10.1002\/clt2.12152","article-title":"Protocol of safe vaccination against COVID-19 in patients with high risk of allergic reactions","volume":"12","author":"Romantowski","year":"2022","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jacig.2022.10.003_bib95","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2021.7517","article-title":"US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021","volume":"325","author":"See","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacig.2022.10.003_bib96","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2022.10.003_bib97","unstructured":"Clinicaltrials.gov. COVID19 SARS vaccinations: systemic allergic reactions to SARS-CoV-2 vaccinations. Last updated: September 21, 2022. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04761822. Accessed May 26, 2022."},{"key":"10.1016\/j.jacig.2022.10.003_bib98","unstructured":"Clinicaltrials.gov. The safety of administering a second dose of a COVID-19 mRNA vaccine in individuals who experienced a systemic allergic reaction to an initial dose. Last Updated: November 14, 2022. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04977479. Accessed May 26, 2022."}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829322000959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829322000959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:09:43Z","timestamp":1757423383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772829322000959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2772829322000959"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2022.10.003","relation":{},"ISSN":["2772-8293"],"issn-type":[{"value":"2772-8293","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The conundrum of COVID-19 mRNA vaccine\u2013induced anaphylaxis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2022.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}